WO2025134073 - METHODS AND COMPOSITIONS FOR TREATING DISEASES OR CONDITIONS INDUCED BY CORTICOSTEROIDS, SYNOVIAL INFLAMMATION, AND DEGENERATIVE JOINT DISEASE
National phase entry is expected:
Publication Number
WO/2025/134073
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063072
International Filing Date
20.12.2024
Title **
[English]
METHODS AND COMPOSITIONS FOR TREATING DISEASES OR CONDITIONS INDUCED BY CORTICOSTEROIDS, SYNOVIAL INFLAMMATION, AND DEGENERATIVE JOINT DISEASE
[French]
MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES OU D'AFFECTIONS INDUITES PAR LES CORTICOSTÉROÏDES, D'UNE INFLAMMATION SYNOVIALE ET D'UNE MALADIE ARTICULAIRE DÉGÉNÉRATIVE
Applicants **
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
UNIVERSITÉ PARIS CITÉ
SORBONNE UNIVERSITÉ
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
UNIVERSITÉ PARIS-SACLAY
INSTITUT GUSTAVE ROUSSY
Inventors
LAMBERTUCCI, Flavia
PAN, Hui
MARTINS, Isabelle
KROEMER, Guido
NOGUEIRA RECALDE, Uxia
KEPP, Oliver
Priority Data
23220140.0
22.12.2023
EP
24150766.4
08.01.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5812 | |
| EPO | Filing, Examination, Granting | 99127 | |
| Japan | Filing, Examination, Granting | 4853 | |
| South Korea | Filing, Examination, Granting | 7511 | |
| USA | Filing, Examination, Granting | 26040 |
Total:
143,343
Contact Us
Abstract[English]
The present disclosure provides improved methods, therapeutic regimens, and systems for treating a disease associated with a pituitary malignancy in a subject, such as treating Cushing Syndrome, or treating one or more symptoms of Cushing Syndrome in subjects, through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods. The present disclosure also relates to compositions for use and methods in treating synovial inflammation in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression. The present disclosure also relates to compositions for use and methods in treating degenerative joint disease, joint inflammation, and manifestations thereof in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression.[French]
La présente divulgation concerne des méthodes, des régimes thérapeutiques et des systèmes améliorés pour traiter une maladie associée à une malignité pituitaire chez un sujet, tel que le traitement du syndrome de Cushing, ou le traitement d'un ou de plusieurs symptômes du syndrome de Cushing chez des sujets, par l'inhibition de l'inhibiteur humain de liaison extracellulaire du diazépam (DBI) par divers procédés. La présente divulgation concerne également des compositions pour utilisation et des méthodes de traitement d'une inflammation synoviale chez un sujet, les compositions pour utilisation et les méthodes comprenant un agent qui réduit l'activité ou l'expression de l'inhibiteur humain de liaison du diazépam (DBI). La présente divulgation concerne également des compositions pour utilisation et des méthodes de traitement d'une maladie articulaire dégénérative, d'une inflammation articulaire et de manifestations de celles-ci chez un sujet, les compositions pour utilisation et les méthodes comprenant un agent qui réduit l'activité ou l'expression de l'inhibiteur de liaison du diazépam (DBI) humain.